Overview

Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate